Latest Posters

Since the end of the 1990’s, the pharmaceutical industry has seen an increased interest in biologics, especially in the therapeutic areas of oncology and inflammation. Here we present the automation of two assays for the characterization and selection of potent antibody drug candidates. Both assays rely on HTRF® detection. The first assay quantifies the binding affinity of antibodies to their target antigen, on live cells.

Objectives of this project were to exploit the database in indian setting to determine nuclear antigens as target for antinuclear antibodies (ANA) in patients of autoimmune hapatitis (AIH) type1.

Suggestions are provided of how efficient industrial bioprocessing can be accomplished, independently of highly expensive molecular biology approaches, in order to recover natural products of medicinal value from wild plant species.

The conventional antibody screening assay based on antibody-antigen binding has been enzyme-linked immunosorbent assay (ELISA). While tedious and consuming, ELISA has proved sufficient for the identification of antibodies directed against secreted antigens. However, cell surface antigens (e.g. GPCRs) provide challenges for ELISA due to the shortage of soluble antigens and high variability resulting from loss of cells during wash procedures.

Much attention has been given to ion exchange (IEX) media as a means to improve productivity as a result of increasing demand for higher efficiency on the downstream process. Until recently, strain optimisation for high productivity and upstream purification were the bottlenecks for most bio-processes.

Escherichia coli (E. coli) has been commonly used for the production of biopharmaceuticals. Among the impurities that must be monitored in biopharmaceuticals is residual host-cell DNA (HCD). This study describes the development and subsequent NDA-level validation of a real time PCR procedure developed in response to a client’s need to improve the sensitivity of detection and quantification of residual E. coli HCD in their drug product.

HBV and HIVenv chips with overlapping oligopeptides encompassing the full amino acid sequences of HBV and HIV polypeptides were produced. In addition, a chip displaying a library of random 4608 different 15-mers peptides (4608-RPL) was prepared. Both chips were used for analyzing monoclonal antibodies and sera from HIV- and HBV-infected individuals. 4608-RPL could be used for identifying target sequences of antibodies without prior knowledge of the corresponding immunizing antigen.

The Nucleofector® Technology enables efficient and reproducible transfection of primary cells and cell lines at throughputs of up to 96 samples per run. Nucleofection® now extends its range of application to deliver small molecules substrates and protein substrates such as peptides, proteins and antibodyconjugates.

Natural Vibrio cholerae infection generates a robust B-cell response that wanes for T-cell independent antigens, suggesting that B-cell responses may be mediated in a T-cell dependent manner. Patients with cholera develop a memory-effector T-cell response to cholera antigens, and B-cell activation occurs after T-cell population expansion, suggesting that T-cells may play an important role in the development and maintenance of memory B-cell responses to T-cell dependent antigens.

To calculate the sensitivity, specificity and positive predictive value of 99 Tc Sestambi scan in the localization of parathyroid disease and to calculate the cost benefit of routine pre-operative scan.